AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Propanc Biopharma Appoints Dr. Ralf Brandt to its Scientific Advisory Board

May 6, 2019

MELBOURNE, Australia--(BUSINESS WIRE)--May 6, 2019--Propanc Biopharma, Inc. (OTCQB: PPCB) (“Propanc”), a biopharmaceutical company developing new cancer treatments for patients suffering from recurring and metastatic cancer, announced today that the Company has appointed Dr. Ralf Brandt to its Scientific Advisory Board (SAB). Dr. Brandt previously served as an Advisory Board member to Propanc over a seven-year period between 2011 and 2018. During this period, he played an instrumental role in advancing Propanc’s lead product candidate, PRP, through early stage and formal preclinical development activities. He is a co-inventor of Propanc’s lead patent family and a co-author of a peer reviewed scientific publication, published by Propanc and its research partners. He will provide significant translational research expertise and clinical support advisory support services to the company’s drug development pipeline.

Dr. Brandt previously stepped down from Propanc’s SAB, as he underwent a merger of his cofounded company, vivo Pharm, a global oncology and immuno-oncology discovery company providing a range of preclinical services with Cancer Genetics, Inc., a Nasdaq listed company enabling precision medicine in oncology from bench to bedside. He currently serves as President of Discovery and Early Development of Cancer Genetics. During Dr. Brandt’s long career in the pharmaceutical industry, he has acquired significant knowledge and expertise in leading business units and representation of services to the preclinical research market, which includes major global pharmaceutical and biotech companies from around the world.

“We are pleased to welcome Dr. Brandt back to our Scientific Advisory Board. He played a pivotal role in advising the company, which enabled us to complete our preclinical development activities for the advancement of PRP to a First-In-Human study in cancer patients,” said James Nathanielsz, Propanc’s Chief Executive Officer. “We look forward to his continued support and guidance, as we now focus our attention towards preparing for the planned clinical trial and progressing PRP through early stage clinical development.”

About Propanc Biopharma, Inc.

Propanc Biopharma, Inc. (the “Company”) is developing a novel approach to prevent recurrence and metastasis of solid tumors by using pancreatic proenzymes that target and eradicate cancer stem cells in patients suffering from pancreatic, ovarian and colorectal cancers. For more information, please visit www.propanc.com.

The Company’s novel proenzyme therapy is based on the science that enzymes stimulate biological reactions in the body, especially enzymes secreted by the pancreas. These pancreatic enzymes could represent the body’s primary defense against cancer.

To view the Company’s “Mechanism of Action” video on anti-cancer product candidate, PRP, please click on the following link: http://www.propanc.com/news-media/video

Forward-Looking Statements

All statements other than statements of historical facts contained in this press release are “forward-looking statements,” which may often, but not always, be identified by the use of such words as “may,” “might,” “will,” “will likely result,” “would,” “should,” “estimate,” “plan,” “project,” “forecast,” “intend,” “expect,” “anticipate,” “believe,” “seek,” “continue,” “target” or the negative of such terms or other similar expressions. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements. These factors include uncertainties as to the Company’s ability to continue as a going concern absent new debt or equity financings; the Company’s current reliance on substantial debt financing that it is unable to repay in cash; the Company’s ability to successfully remediate material weaknesses in its internal controls; the Company’s ability to reach research and development milestones as planned and within proposed budgets; the Company’s ability to control costs; the Company’s ability to obtain adequate new financing on reasonable terms; the Company’s ability to successfully initiate and complete clinical trials and its ability to successful develop PRP, its lead product candidate; the Company’s ability to obtain and maintain patent protection; the Company’s ability to recruit employees and directors with accounting and finance expertise; the Company’s dependence on third parties for services; the Company’s dependence on key executives; the impact of government regulations, including FDA regulations; the impact of any future litigation; the availability of capital; changes in economic conditions, competition; and other risks, including, but not limited to, those described in the Company’s Registration Statement on Form S-1, filed with the U.S. Securities and Exchange Commission (the “SEC”) on February 25, 2019, and in the Company’s other filings and submissions with the SEC. These forward-looking statements speak only as of the date hereof and the Company disclaims any obligations to update these statements except as may be required by law.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190506005033/en/

CONTACT: James Nathanielsz

Propanc Biopharma, Inc.

Investor Relations

irteam@propanc.com

+61-03-9882-6723

KEYWORD: AUSTRALIA AUSTRALIA/OCEANIA

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY ONCOLOGY PHARMACEUTICAL

SOURCE: Propanc Biopharma, Inc.

Copyright Business Wire 2019.

PUB: 05/06/2019 08:30 AM/DISC: 05/06/2019 08:30 AM

http://www.businesswire.com/news/home/20190506005033/en